Jin Rong Jie·2025-08-05 10:39Group 1 - The core viewpoint of the news is that the CSI Hong Kong 300 Biopharmaceutical Index has shown significant growth, with a 24.33% increase over the past month, a 60.33% increase over the past three months, and a remarkable 137.42% increase year-to-date [1] - The CSI Hong Kong 300 Industry Index series is categorized according to the China Securities Index industry classification standards, reflecting the overall performance of different industries in the Hong Kong market [1] - The CSI Hong Kong 300 Biopharmaceutical Index is composed entirely of securities from the Hong Kong Stock Exchange, with 100% of its holdings in the biopharmaceutical sector [1] Group 2 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, but can be modified in the event of temporary adjustments due to changes in the underlying index samples [2] - Special events affecting sample companies, such as delisting or mergers, will lead to corresponding adjustments in the CSI Hong Kong 300 Industry Index series [2]